TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05634707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Patients randomized to the experimental arm will receive fluoxetine 20mg/day for 5 days before escalation to a maintenance dose at day 6. On day 6, patients will start treatment with 50 mg/m2 TMZ daily for 7 days (Days 6-12)~* Arm 2A (n=10) - Escalate to maintenance 40mg/day fluoxetine on day 6~* Arm 2B (n=10) - This arm will be opened as long as there are less than 3/10 dose limiting toxicities in Arm 2A. Patients will escalate to maintenance 60mg/day fluoxetine on day 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Patients randomized to the control arm will receive 50 mg/m2 temozolomide daily for 7 days (Days 1-7), followed by resection or biopsy 21 days after initiation of the temozolomide cycle.
Study: NCT06149091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid；
Description: Tranexamic acid (TXA) is an antifibrinolytic drug that competitively inhibits the activation of plasminogen. After its efficacy and safety were confirmed in several randomized controlled trials, both systemic and topical administration of TXA have been widely used for hemostasis in trauma and various surgical settings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: In diagnostic bronchoscopy, one of the most commonly used topical hemostatic agent is epinephrine. The primary mechanism of epinephrine is vasoconstriction, leading to reduced blood flow and hemostasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemagglutinase
Description: Thrombin injection (Batroxobin) is an enzymatic hemostatic agent refined from the venom of the Brazilian lancehead snake. It promotes clot formation at the bleeding site, characterized by rapid and effective hemostasis and high safety. It is now widely used for clinical prevention and treatment of perioperative bleeding and oozing. Multiple randomized controlled studies have evaluated the safety and efficacy of intravenous/topical application of thrombin in various trauma and surgical settings.
Study: NCT06572774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C3Link Strategies
Description: Education sessions and community liaison support to link to services

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C3Link Strategies
Description: Education sessions and community liaison support to link to services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: C3Link Strategies
Description: Education sessions and community liaison support to link to services
Study: NCT06207669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy will be applied to individuals in the clinic for 30 minutes after the 2nd hour of each hemodialysis session for 4 weeks.
Study: NCT06331130

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography
Description: Computed Tomography done according to Clinical Practice to assess mesenteric involvment

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography
Description: Computed Tomography done according to Clinical Practice to assess mesenteric involvment
Study: NCT06222658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharmaco-mechanichal thrombectomy
Description: pharmaco-mechanichal thrombectomy in acute limb ischemia
Study: NCT04622267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barbed suture
Description: to close a C-section incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard antimicrobial suture
Description: to close a C-section incision
Study: NCT03508479

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RG-HRV16
Description: 0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
Study: NCT05781503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity Capital Intervention (Coach + Co-designed Leadership Guide)
Description: Young people randomized to the intervention group will engage in a co-designed leadership guide with their assigned coach. The co-designed leadership guide contains 12 chapters with the overarching aim of enhancing identity capital along with providing strategies to achieve participant-identified goals. Each chapter contains four activities (e.g., self-reflection exercise or listening to a podcast). Ideally, youth will complete one chapter every month. Each young person in this group will meet individually with their coach every two weeks and with a larger group of 10 youth participants and their coach every month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Rent Subsidies
Description: All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Rent Subsidies
Description: All study participants will receive a monthly rent subsidy ($800 for those living in Toronto; $700 for those living in St. Catharine's or Hamilton due to differences in cost of living) for 12 months.
Study: NCT04722809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Description: Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QOL-Brux
Description: Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscular strength of the jaw
Description: Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.~At inclusion and 1 month post-injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensity and frequency of episodes of nocturnal bruxism
Description: Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
Study: NCT04867057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichomylin for SAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichomylin for MAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MAD
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
Study: NCT05763212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Walking+Baseline treatment
Description: Reverse Walking+Baseline treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration + Reverse Walking+Baseline treatment
Description: Whole Body Vibration + Reverse Walking+Baseline treatment
Study: NCT04718961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volixibat
Description: Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules matched to study drug minus active substance.
Study: NCT04722809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual analogue pain scale
Description: Evaluation of jaw pain. At inclusion and 3 months post-injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endobuccal and linea alba photographs
Description: anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).~At inclusion
Study: NCT06569589

Intervention type: DIAGNOSTIC_TEST
Intervention: 23NaMRI Scan
Description: 23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.
Study: NCT05137704

Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study: NCT05708820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education programme
Description: Online group will follow the education programme through videos that they can view at any time and a live session to answer questions.
Study: NCT06556472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: 1. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norephrine
Description: 1. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norephrine
Description: 1. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
Study: NCT06353750

Intervention type: OTHER
Intervention: Magnesium supplement
Description: Intravenous magnesium supplement (10mmol).

Intervention type: OTHER
Intervention: Magnesium supplement
Description: Intravenous magnesium supplement (10mmol).

Intervention type: OTHER
Intervention: Magnesium supplement
Description: Intravenous magnesium supplement (10mmol).
Study: NCT05557656

Intervention type: DRUG
Intervention: Regorafenib 40 MG
Description: participants who received the treatment of Regorafenib
Study: NCT05708820

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education programme
Description: Face-to-face educacion programme in a group session
Study: NCT06285006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin is a synthetic analogue of ADH released by the posterior pituitary gland that reduces urine production by increasing water reabsorption by the collecting tubules.
Study: NCT05316389

Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Muscle sparing Latissimus Dorsi Flap or prothesis

Intervention type: PROCEDURE
Intervention: Breast reconstruction
Description: Muscle sparing Latissimus Dorsi Flap or prothesis
Study: NCT04980456

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A contact lenses
Description: Investigational silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study: NCT05771155

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) infusions
Description: Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) infusions
Description: Intravenous (IV) infusions of a dose of 300mg, on Weeks 0, 2 and 6, 14, 22, 30, 38 and 46
Study: NCT06449417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Aurora Training
Description: Patients will be asked to record their physical activity in the logbook every week, at the end of the intervention, each patient will have to dedicate a letter to another patient who will receive the same Aurora Kit.
Study: NCT06246058

Intervention type: BEHAVIORAL
Intervention: Partner support
Description: The intervention group's survey vignette will include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.

Intervention type: BEHAVIORAL
Intervention: Formal recruiter attire
Description: The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~FORMAL dress code of the recruiter is the intervention in this case, defined as clinical attire alluding to some clinical authority.

Intervention type: BEHAVIORAL
Intervention: Without Partner support
Description: The intervention group's survey vignette will NOT include a component of partner support which serves as the key behavioral manipulation tested for this study's primary outcome.

Intervention type: BEHAVIORAL
Intervention: Casual recruiter attire
Description: The SWAT will separately test recruitment rates - as measured by rate of survey completion divided by total number of individuals approached - based on how the recruiters are dressed.~CASUAL dress code of the recruiter is the intervention in this case.
Study: NCT05464030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9140
Description: M9140 will be administered at an escalated dose until Maximum tolerated dose (MTD) and/or a safe recommended Dose for Expansion (RDE) is determined in Part 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9140
Description: M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9140
Description: M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9140
Description: M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9140
Description: M9140 will be further investigated in part 2 of the study and includes dose optimization, an alternative administration regimen and combination regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously as per standard of care.
Study: NCT06544122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Anodal tDCS will be applied at an intensity of 2mA and duration of 20 minutes. The assembly of the electrodes during the tDCS sessions will be carried out as follows: primary motor cortex, the stimulation electrode (anode) will be positioned on C5 (international EEG 10-20 system), in S1 (2cm posterior to C5), at the PFCDL (Fp3), all with the cathode positioned on the region contralateral supraorbital. For cerebellar tDCS the anode will be positioned on the inion area and the cathode on the deltoide muscle.
Study: NCT05464030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally as per standard of care.
Study: NCT05247398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stability Exercise Program
Description: The thumb CMC DS intervention involves four 60-minute occupational therapy visits as well as a daily home program across a 8-week period. Clinic visits focus primarily on home program coaching, and progression of the exercise regimen. Home programs involve daily exercises which follow the intensity and duration recommended for older adults.
Study: NCT04980456

Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide-based cleaning and disinfecting solution
Study: NCT05623852

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fucoidan
Description: It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.
Study: NCT05878431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology
Description: The patients in the experimental group underwent 12 sessions of foot reflexology in a quiet room, twice a week, for 6 weeks. No application was made to the patients in the control group.~FOOT REFLEXOLOGY APPLICATION STAGES~* Application of heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts about 3 minutes,~* Pressure on the brain, cervical region, solar plexus (the projection of the central nervous system on the sole of the foot), lymph system, adrenal glands, urinary system, digestive system, sciatic nerve, hips, knees and reflex points on the soles of the legs for about 10-15 minutes. implementation (Figure 3.4),~* Ending the application by applying heating methods such as Achilles tendon stretching, wrist loosening, walking the thumbs of both hands on the soles of the feet and wringing the laundry, which lasts approximately 3 minutes after the application.
Study: NCT05273736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Behavioral Change Techniques
Description: 1. Goal setting: set or agree on a goal defined in terms of behavior to be achieved. Example: Set the goal to take your medication as prescribed tomorrow.~2. Action planning: prompt detailed planning of performance of behavior (must include a setting, frequency, duration, and intensity). Example: Develop a plan for taking your medication.~3. Self-Monitoring of behavior: establish a method for person to monitor and record their behavior. Example: Did you take your statin medication today?~4. Feedback on behavior: Monitor and provide informative or evaluative feedback on performance of the behavior (e.g. form, frequency, duration, intensity). Example: You did not take your statin medication as prescribed yesterday.~5. Prompts/Cues: introduce or define environmental or social stimulus with the purpose of prompting or cueing the behavior. The prompt or cue would normally occur at the time or place of performance. Example: Please remember to take your medication soon.
Study: NCT05305573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine HIPRA 40 ug/dose
Description: Subjects will receive one injection of COVID-19 Vaccine HIPRA (PHH-1V)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty (Pfizer-BioNtech) 30 ug/dose concentrate for dispersion for injection
Description: Subjects will receive one injection of Comirnaty Vaccine
Study: NCT06238973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Low
Description: In order to maintain arterial blood pressure within the range of 50-57 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Middle
Description: In order to maintain arterial blood pressure within the range of 58-65 mmHg, Sevoflurane at a concentration of 0.5-1 MAC and Remifentanil at a rate of 0.05-0.3 mcg/kg/min will be used. If additional hypotensive agents are required, an infusion of Esmolol at a rate of 25-200 mcg/kg/min will be initiated.
Study: NCT04612075

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET/MRI
Description: Performed at baseline, interim and at 12-16 weeks post radiotherapy.
Study: NCT06323083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: Emotional freedom techniques is a psychophysiological intervention that combines psychological methods from traditional therapies with somatic stimulation. EFT involves tapping acupuncture points to desensitize negative emotions by focusing on the emotion.
Study: NCT06510686

Intervention type: OTHER
Group type: OTHER
Intervention: İnspiratory muscle training
Description: exercises to strengthen inspiratory muscles

Intervention type: OTHER
Group type: OTHER
Intervention: İnspiratory muscle training
Description: exercises to strengthen inspiratory muscles

Intervention type: OTHER
Group type: OTHER
Intervention: Core training
Description: exercises to strengthen inspiratory and core muscles
Study: NCT05737628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYON4228 + Rituximab
Description: 20 mg/mL BYON4228 in 8 mL solution for infusion.~Rituximab 500 mg concentrate for solution for infusion.
Study: NCT05892289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted proximal gastrectomy with double-flap technique
Description: Patients in this group receive robotic assisted proximal gastrectomy with D1+/D2 lymph node dissection(D1+ for stage IA：Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p；D2 for stage IB: Nos.1, 2, 3a, 4 sa, 4 sb, 7, 8a, 9，11p and 11d).The double-flap technique is used for the digestive tract reconstruction.
Study: NCT05879666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online educational phthalate course
Description: This is an online course focused on phthalates for reproductive health professionals. It consists of videos from patient, scientist, and OBGYN perspectives describing how phthalates relate to reproductive health. There is also an interactive module and worksheet to facilitate conversations about phthalates with pregnant individuals.
Study: NCT05343884

Intervention type: RADIATION
Group type: OTHER
Intervention: Myocardial perfusion imaging
Description: Myocardial perfusion imaging

Intervention type: RADIATION
Group type: OTHER
Intervention: Myocardial perfusion imaging
Description: Myocardial perfusion imaging